Ramoplanin as a novel therapy for Neisseria gonorrhoeae infection: an in vitro and in vivo study in Galleria mellonella

J Med Microbiol. 2024 Jan;73(1). doi: 10.1099/jmm.0.001785.

Abstract

Neisseria gonorrhoeae is a bacterial pathogen that causes gonorrhoea, a sexually transmitted infection. Increasing antimicrobial resistance in N. gonorrhoeae is providing motivation to develop new treatment options. In this study, we investigated the effectiveness of the antibiotic ramoplanin as a treatment for N. gonorrhoeae infection. We tested the effectiveness of ramoplanin in vitro against 14 World Health Organization (WHO) reference strains of N. gonorrhoeae and found that it was active against all 14 strains tested. Furthermore, in a Galleria mellonella infection model of N. gonorrhoeae WHO P, we demonstrated that ramoplanin was active in vivo without any evidence of toxicity. This suggests that ramoplanin might be a new promising antibiotic treatment for gonorrhoea.

Keywords: AMR; Neisseria gonorrhoeae; lantibiotics; lipid II; ramoplanin; resistance.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Depsipeptides* / pharmacology
  • Drug Resistance, Bacterial
  • Gonorrhea* / drug therapy
  • Gonorrhea* / microbiology
  • Humans
  • Microbial Sensitivity Tests
  • Neisseria gonorrhoeae

Substances

  • ramoplanin
  • Anti-Bacterial Agents
  • Depsipeptides